Aspen Aerogels, Inc. Files 2025 Form 10-K/A: Key Details for Investors

Overview

Aspen Aerogels, Inc. (ASPN), a leading provider of aerogel-based products, has filed its Amendment No. 1 to its Annual Report for the fiscal year ended December 31, 2025. The amendment addresses a critical correction in its audited financial statements and internal controls, filed with the SEC on March 23, 2026. The company’s common stock is listed on the New York Stock Exchange under the trading symbol ASPN. As of March 10, 2026, Aspen Aerogels had 82,825,603 shares of common stock outstanding.

Key Points from the Report

• Correction of Inventory Figure in Audit Report:
  • The amendment corrects a “scrivener’s error” in the previously filed audit report by KPMG LLP. The original filing mistakenly reported the inventories balance as \$47.6 million as of December 31, 2025, which was actually the balance as of December 31, 2024.
  • The correct inventories balance for December 31, 2025 is \$38.2 million, as reflected in the amended audit report.
  • The correction is specifically highlighted under the section “Critical Audit Matters – Net realizable value of certain inventories” in the audit report.
• Financial Position and Performance:
  • Aspen Aerogels’ audited consolidated financial statements for the years ended December 31, 2025, 2024, and 2023 present the company’s financial position, results of operations, and cash flows. The audit confirms that the statements are in conformity with U.S. GAAP.
  • Total assets as of December 31, 2025: \$406.7 million
  • Total current assets as of December 31, 2025: \$242.1 million
  • Total assets as of December 31, 2024: \$895.1 million (note: likely includes the previously misstated inventory figure)
  • Current liabilities: Detailed in the balance sheet, including finance obligations for sale and leaseback transactions (\$4.4 million) and current portion of long-term debt (\$25.1 million)
• Internal Controls and Audit:
  • KPMG LLP has provided an unqualified opinion on the company’s internal control over financial reporting, stating that Aspen Aerogels maintained effective internal control as of December 31, 2025.
  • The management’s assessment of internal controls is included in the report.
  • There were no material weaknesses identified.
• Critical Audit Matters:
  • The audit report draws attention to the net realizable value of certain inventories as a critical audit matter. The valuation relied on market rent ranges, discount rates based on investor surveys, and terminal capitalization rates derived from comparable property sales.
  • This area involved especially challenging and complex judgment from the auditors.
• Corporate Structure and Reporting:
  • Aspen Aerogels is not a large accelerated filer, not an emerging growth company, and not a well-known seasoned issuer.
  • The company is compliant with all required filings and regulations.
  • No restatements or corrections requiring a recovery analysis of incentive-based compensation for executive officers were made.
• Proxy Statement Reference:
  • Portions of the definitive Proxy Statement for the Annual Meeting of Stockholders (scheduled for May 13, 2026) are incorporated by reference into Part III of the Annual Report.

Potentially Price-Sensitive Information

• Correction of Inventory Balance: The inventory correction from \$47.6 million to \$38.2 million could be significant for investors tracking working capital, liquidity, and operational efficiency. A lower inventory balance may affect perceived asset quality and could impact analyst models or investor sentiment.
• No Other Material Changes: The amendment does not update any other information in the original filing nor reflect events occurring after March 13, 2026. Investors should note this amendment is purely a correction and not indicative of new developments or operational changes.
• Audit Confidence: The unqualified audit opinion and absence of material weaknesses in internal controls provide reassurance regarding the integrity of Aspen Aerogels’ financial reporting.

Important Details for Shareholders

• Aspen Aerogels remains compliant with SEC filing requirements and maintains effective internal controls.
• Shareholders should review the amended inventory figure when evaluating the company’s liquidity, asset management, and overall financial health.
• The correction of the inventory balance does not impact the company’s overall audit opinion or its compliance status.
• No restatements requiring incentive-based compensation recovery, and no new information regarding executive compensation, litigation, or business developments.

Conclusion

The main news from Aspen Aerogels’ Form 10-K/A is the correction of a material figure in its audit report, specifically the inventories balance. This correction is potentially price-sensitive as it affects the reported current assets and may influence investor perceptions and trading activity. No other material changes or updates are included in the amendment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filing and consult their financial advisors before making any investment decisions. The correction in the inventory figure may affect certain financial ratios and analyst models; however, no other material changes are reported in this amendment.

View ASPEN AEROGELS INC Historical chart here